去年净利润预计暴跌超200%，联环药业出现上市首亏

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is expected to report a net loss of between 83 million to 99 million yuan for the year 2025, marking its first annual loss since going public, with a year-on-year decline of 217.63% to 198.62% [2][3] Financial Performance - In 2024, the company experienced a slight decline in revenue, achieving 2.16 billion yuan, a decrease of 0.63% year-on-year; net profit attributable to shareholders fell by 37.66% to 84.16 million yuan, while the net profit after deducting non-recurring items dropped by 56.89% to 49.87 million yuan [3] - The projected net loss for 2025 represents a decrease of 166.7 million to 183 million yuan compared to the previous year, with a decline exceeding 200%; the net profit after deducting non-recurring items is expected to be a loss of 32.5 million to 39 million yuan, down by 82.37 million to 88.87 million yuan [3] Regulatory Impact - The company faced a significant antitrust fine of 61.04 million yuan, which directly impacted its net profit; this fine accounted for 72.53% of the audited net profit for 2024 and 2.83% of the annual revenue, leading to a direct reduction of 61.04 million yuan in the projected net profit for 2025 [4] Operational Challenges - The company is under pressure from industry policy adjustments, high R&D costs, and restricted financing channels, which have contributed to its declining performance; the core product's gross margin is under pressure due to national drug procurement policies and increased international market competition [5] - The price of dexamethasone phosphate sodium, a key raw material, has plummeted to between 0.23 yuan and 0.57 yuan per unit post-antitrust penalty, significantly lower than the maximum price of 98.76 yuan during the period of monopoly, compressing the profitability of related businesses [5] R&D and Financing - The company has been increasing its R&D investment significantly, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, averaging over 30% annual growth; however, this sustained investment continues to pressure profit margins [5] - The company has faced challenges in financing, with two failed fundraising attempts in 2024 totaling 7.35 million yuan, which were terminated due to "market environment changes and the company's actual operating conditions"; it has since sought debt financing, applying for a 240 million yuan R&D loan [6] Future Outlook - The company is exploring how to address the profit gap created by the antitrust fine and whether the 240 million yuan R&D loan will be successfully secured; there are concerns regarding its cash flow situation and how it will restructure its core profit segments to achieve profitability [7]